Preferred Label : Anti-PD-L1/CD27 Bispecific Antibody CDX-527;
NCIt synonyms : PD-L1xCD27 Bispecific Antibody CDX-527; Anti-PD-L1/Anti-CD27 Bispecific Antibody CDX-527;
NCIt definition : A bispecific antibody directed against both the immunosuppressive ligand programmed
cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and the cell
surface antigen CD27, with potential immune checkpoint inhibitory, immunostimulatory
and antineoplastic activities. Upon administration, anti-PD-L1/CD27 bispecific antibody
CDX-527 targets and binds to both PD-L1 expressed on tumor cells and CD27 expressed
on a variety of immune cell types, including most T-lymphocytes. This prevents the
binding of PD-L1 to its receptor, programmed cell death protein 1 (PD-1, CD279), inhibits
the PD-1-mediated signaling and induces CD27-mediated signaling. This inhibits the
PD-1-mediated downregulation of T-cell activation and proliferation, and enhances
CD27-mediated responses, including the expansion of antigen-activated T-cells and
the cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. This
restores immune function and activates a sustained cytotoxic T-lymphocyte (CTL)-mediated
immune response against tumor cells. PD-L1, which is overexpressed in many human cancer
cell types, plays an important role in the downregulation of the immune system and
tumor evasion from host immunity. CD27, a co-stimulatory molecule and member of the
tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes,
memory B-cells and natural killer (NK) cells. It plays an important role in NK cell-mediated
cytolytic activity and T- and B-lymphocyte proliferation and activation.;
Molecule name : CDX-527; CDX 527;
NCI Metathesaurus CUI : CL1642782;
Origin ID : C176983;
UMLS CUI : C5447534;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
